| REVIEW ARTICLE |
|
| Year : 2022 | Volume
: 12
| Issue : 4 | Page : 394-408 |
|
|
Central serous chorioretinopathy: Treatment
Jong Beom Park, Kiyoung Kim, Min Seok Kang, Eung Suk Kim, Seung-Young Yu
Department of Ophthalmology, Kyung Hee University Hospital, Kyung Hee University, Seoul, Korea
Correspondence Address:
Prof. Seung-Young Yu
Department of Ophthalmology, Kyung Hee University Hospital, 23, Kyungheedae-ro, Dongdaemun-Gu, Seoul 02447
Korea
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/2211-5056.362040
|
|
|
Central serous chorioretinopathy (CSC) is a pachychoroid spectrum disease characterized by serous detachment of the neurosensory retina with subretinal fluid in young and middle-aged adults. The pathogenesis of CSC is not yet fully understood. However, it is considered a multifactorial disease that is strongly associated with choroidal dysfunction or vascular engorgement. Although there is no consensus on the treatment of CSC, photodynamic therapy has been effectively used to manage serous retinal detachment (SRD) in CSC. Moreover, micropulse diode laser photocoagulation and focal laser treatment have also been used. Recently, oral medications, including mineralocorticoid receptor antagonists, have been proposed for the management of CSC. Multimodal imaging plays a significant role in the diagnosis and treatment of CSC. Optical coherence tomography angiography (OCTA) has the advantage of detecting vascular flow in the retina and choroid layer, allowing for a better understanding of the pathology, severity, prognosis, and chronicity of CSC. In addition, early detection of choroidal neovascularization in CSC is possible using OCTA. This review article aims to provide a comprehensive and updated understanding of CSC, focusing on treatment.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
